(Received for publication, December 23, 1996)
From the Burnham Institute, San Diego, California 92037 and the Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109
When ectopically expressed in animal cells,
cytokine response modifier A (CrmA), a product of the cowpox virus,
prevents programmed cell death initiated by a variety of stimuli. Since
CrmA is a proteinase inhibitor, its target is probably a protease that
promotes cell death. The identification of this target is crucial in
delineating essential regulation points that modulate the apoptotic
program. We have compared the kinetics of interaction of CrmA with five proteases that may play a role in apoptosis. Four of the proteases, all
members of the caspase family, are inhibited with widely different rates and affinities ranging over 5 orders of magnitude. One is not
inhibited at all under the experimental conditions. CrmA is quite
selective in its ability to inhibit caspases, showing the highest
affinity for interleukin-1-converting enzyme and the second highest
for the caspase FLICE (Ki = 0.95 nM), identified as a component of the intracellular signaling complex recruited by ligation of the death receptor Fas. On the basis of
comparative inhibitor kinetics, we propose that CrmA is unlikely to
inhibit the caspases Yama, Mch2, or LAP3 in vivo but that
its inhibition of FLICE is of a magnitude for this protease to be a key
target of CrmA during Fas-mediated apoptosis. Therefore, our results
support the hypothesis that FLICE catalyzes a crucial step in the
promotion of cell death.
The cowpox viral serpin known as cytokine response modifier A
(CrmA)1 is a strong inhibitor of the
cysteine protease interleukin-1-converting enzyme (ICE) (1, 2),
which is responsible for the proteolytic activation of interleukin-1
precursor (3, 4). ICE is a homolog of the ced-3 gene product
(5), which plays a key role in the precisely controlled programmed cell
death during development of the nematode Caenorhabditis
elegans. On the basis that the mammalian Ced-3 counterpart should
be an ICE-like protease, several groups have used CrmA as a tool to
define promoters of cell death. Thus, CrmA is able to prevent apoptosis
induced by tumor necrosis factor or Fas ligand (6-8), serum withdrawal
(9), nerve growth factor withdrawal (10), as well as detachment from
the extracellular matrix (11). This implies that CrmA has an additional
function to the one ascribed to it in limiting the generation of mature interleukin-1
by inhibiting ICE and suggests that a CrmA-inhibitable protease is a key component of programmed cell death in several distinct systems.
Although ICE was at first thought to be the natural candidate, the results of gene ablation experiments question its role in apoptosis (12, 13). However, a family of ICE-like proteases has been identified by homology screening of nucleic acid data bases using ICE and Ced-3 sequences, and some have been implicated as key components of the suicide machinery. At present the family, now referred to as "caspases" (14), consists of Ced-3 and the following 10 human proteins: ICE, Ich1, Yama, Mch2, LAP3, ICErel-II, ICErel-III, ICELAP6, Mch4, and FLICE. Other names for the family members are compiled in Ref. 14. Each caspase contains characteristic conserved sequences important for proteolytic activity and is able to cause apoptosis when overexpressed ectopically in recipient cells. However, which, if any, are the targets of CrmA is not clear, as studies to date are insufficient to settle the question. For example, there is some evidence that caspases other than ICE can be inhibited by CrmA, but the inhibition is rather weak. Presumably, the target(s) should be rapidly and strongly inhibited. One way to determine such a target is to analyze the kinetics of CrmA inhibition of the candidate caspases Mch2, Yama, LAP3, and FLICE that have been implicated in the Fas-mediated pathway to cell death.
Full-length cDNAs encoding Yama, Mch2, and LAP3 and a cDNA encoding the catalytic chains of FLICE (starting with Ser-217 and ligated downstream of the vector sequence MGSSHHHHHHSSGLVPRGSHM) were cloned into pET23b or pET15b (Novagen) and expressed in Escherichia coli strain BL21(DE3)pLysS (15). Codon 217 of the FLICE precursor was chosen since the fragment 1-216 is found associated with the presumptive pro-FLICE activator complex in vivo. Yama, Mch2, and LAP3 contained C-terminal His6 tags, and FLICE contained an N-terminal His6 tag. N-terminal sequencing of each recombinant protease confirmed purity and demonstrated that the following cleavage sites resulted from removal of the N-terminal peptides and generation of the large and small subunits: Mch2 at Asp-23 and -193; Yama at Asp-28 and -175 (minor cleavage at Asp-179); LAP3 at Asp-23 and -206 (minor cleavage at Asp-198); and FLICE at Asp-385 (no removal of the N-terminal vector sequence). His6 tagged CrmA was expressed using E. coli strain TG1 as described previously (16). All tagged proteins were purified by affinity chromatography on Ni2+-nitrilotriacetate-agarose (Qiagen) or Pharmacia Biotech Inc. chelating Sepharose charged with NiSO4 according to the manufacturer's instructions.
Substrates for Enzyme AssaysThe fluorogenic substrate benzyloxycarbonyl-Tyr-Val-Ala-Asp-7-amino-4-trifluoromethyl-coumarin (Z-YVAD-AFC) for ICE and benzyloxycarbonyl-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl-coumarin (Z-DEVD-AFC) for the other four caspases were purchased from Enzyme Systems Products and dissolved in dimethyl formamide as a 10 mM stock solution.
Enzyme AssaysCaspase activity was determined by measuring the release of AFC from the synthetic substrates using continuous recording instruments. Enzyme activities at high concentration were analyzed using a SpectraMAX 340 plate reader (Molecular Devices) at 380 nm in the kinetic mode at 37 °C. Assay buffer was 50 mM Hepes, pH 7.4; 100 mM NaCl, 0.1% Chaps, 10 mM dithiothreitol, and 10% sucrose. Enzyme activities at lower concentrations were assayed by using a LS50B fluorometric plate reader (Perkin-Elmer) in the kinetic mode at 37 °C. The excitation and emission wavelengths were 400 nm and 505 nm, respectively. Assay buffer is the same as described above. Values of Km for the cleavage of Z-DEVD-AFC by FLICE, Mch2, Yama, and LAP3 were calculated in the substrate range of 10-1000 µM, and data were analyzed by Eadie-Hofstee plots.
Kinetic Analysis of Enzyme Assay DataInhibition rates and equilibria were determined by the method of progress curves, where a reaction was initiated by the addition of enzyme to a mixture of substrate and inhibitor. Inhibitor concentration was kept at a large excess of enzyme to render the reaction pseudo-first order for convenience of analysis. Calculations of kinetic parameters are based on a single-step reaction scheme (see "Results and Discussion" for more details). The observed inhibition constant in the presence of substrate, Ki(app), is given by,
![]() |
(Eq. 1) |
![]() |
(Eq. 2) |
![]() |
(Eq. 3) |
![]() |
(Eq. 4) |
Protein samples were analyzed by non-denaturing PAGE or reduced SDS-PAGE in gels of 5-15% linear acrylamide gradients (18). Protein bands were visualized by Coomassie Blue R250 staining.
The caspases were obtained predominantly as the processed two chain forms with yields of 0.5-1.0 mg/liter of induced culture and judged to be more than 95% pure by SDS-PAGE and N-terminal sequence analysis. Caspase concentrations were determined from their observed absorbance at 280 nm and molar extinction coefficients were calculated according to Ref. 19. The mechanism of processing that results in the conversion of the precursors to active two-chain proteases in E. coli is unknown. The CrmA recombinants were obtained in purified form with a yield of about 3.7 mg/liter of induced culture.
When CrmA was incubated with ICE the cleavage of substrate was almost
completely abrogated (Fig. 1), consistent with previous analysis of the ICE-CrmA interaction (2). Significantly, inhibition of
FLICE by CrmA was also very potent. Inhibition of Mch2 and Yama was
much weaker and slower, while no inhibition of LAP3 was observed for up
to 6.7 µM CrmA. Representative progress curves for the
inhibition of FLICE and Mch2 are shown in Fig. 2. After variable relaxation times, corresponding to the association of protease
with inhibitor, steady states of product formation were observed from
which Ki values were calculated according to
Equations 1 and 2, and tabulated in Table I.
|
The first order rate constants (kobs) for the
interaction of CrmA with FLICE, Mch2, Yama, and LAP3 were determined by
analysis of the association phase (Fig. 2) as described in Equation 3
and plotted against inhibitor concentration to derive ka
values, according to Equation 4. Fig. 3 demonstrates the
analysis of association rates of CrmA with FLICE, Mch2, and Yama, and
the respective ka values determined from these plots are
listed in Table I. The inhibition rates correlated with
Ki values to demonstrate the same order of
efficiency of inhibition. The equilibrium and rate constants derived
from the data are global constants, the exact meanings of which depend
upon the reaction mechanisms. As is the case with most protein
inhibitors of proteases, the mechanism is probably two-step. Indeed,
this is indicated by deviation from linearity in the
kobs/I plot at high inhibitor concentration, most
obvious in the case of Mch2 (Fig. 3). Irrespective of the number of
steps in the inhibitory pathway of the caspases, their relative
specificity of inhibition by CrmA would not be dependent on the
mechanisms involved. In each case we were able to observe final steady
states of substrate hydrolysis in large inhibitor excess, indicating
that the inhibition of FLICE, Mch2, and Yama by CrmA is reversible.
This was not detectable with ICE, as previously reported (2), because
of the extreme strength of that interaction.
Complex Formation and Analysis by PAGE
FLICE or Mch2 were
incubated with an excess of CrmA and samples analyzed by SDS- and
non-denaturing PAGE. Sample gels for FLICE and Mch2 are shown in Fig.
4, which demonstrates that a unique protein band
consistent with a complex between each of the caspases and CrmA can be
identified in non-denaturing PAGE. The complex is dissociated by
boiling in SDS. Turnover of CrmA is visible on SDS-PAGE as denaturation
of the complexes results in the appearance of a cleavage product of
CrmA, which probably resides in the reactive site loop as observed with
most serpin-protease complexes (20, 21). Similar results were obtained
with Yama, and as expected, no complex was observed with LAP3 (data not
shown). Because complexes of CrmA with the caspases are kinetically
reversible and not stable to SDS, they are unlike most serine
protease-serpin complexes. The detailed mechanism of inhibition of
caspases by CrmA is under investigation in our laboratory, but our
observations confirm that the cross-class inhibitory activity of
serpins first demonstrated with ICE (2) is a general phenomenon for a
number of caspases.
In Vivo Implications
Since CrmA is an extremely good
inhibitor of ICE, it was originally thought that this would be the
inhibitor's target. This is probably correct in the context of
interleukin-1 processing but not likely during apoptosis. Though
CrmA does not protect against apoptosis triggered by all stimuli, the
extent to which it protects against Fas-mediated death, for example, is
remarkable. Cells that express CrmA survive and replicate in the
presence of lethal levels of Fas antibody, and so proteolysis mediated by a CrmA-inhibitable protease is essential in the Fas death pathway (8, 22). We demonstrate here that three of four caspases implicated in
apoptosis are inhibited by CrmA. This does not mean that all three are
likely targets for CrmA in vivo. Earlier studies suggested
that Yama might be a target of CrmA (22). Doubts were raised because
the inhibition of Yama by CrmA, although appreciable under experimental
conditions, would be kinetically unfavorable (23). The inhibition of
Mch2 is faster and tighter than Yama, but it too is unlikely to be a
target based on the same criteria.
Though the target of a protease inhibitor cannot be elucidated solely on kinetic evidence, it is more straightforward to rule out targets. Thus, if neither Mch2, Yama, nor LAP3 could be considered targets, they cannot be at a key location in the apoptotic pathway triggered by Fas ligation. Because CrmA prevents the activation of these three caspases in vivo (24, 25), the CrmA target must be upstream. FLICE is inhibited more than 2 orders of magnitude faster and tighter than Mch2 and on this basis is a much likelier candidate for the CrmA target of Fas-initiated apoptosis. The demonstration that the FLICE precursor is a component recruited to the death-initiating complex during Fas ligation (26, 27) places it in an upstream position expected for the CrmA target. Thus, of the four caspases implicated in Fas-mediated apoptosis, FLICE is the clearest CrmA target.
We thank Annamarie Price and Manish Garg for technical assistance and Ed Madison, Kevin Tomaselli, and our colleagues at the Burnham Institute for helpful discussions.